多药耐药相关蛋白基因和P-糖蛋白在恶性淋巴瘤中的表达与意义  

Significance of Multidrug Resistance- Associated Protein Gene and P- gp Expression in Malignant Lymphomas

作　　者：杨锡贵[1] 魏玲[2] 宋恕平[1] 贾丽雅[2] 

机构地区：[1]山东省肿瘤防治研究院内科,山东济250117 [2]山东省肿瘤防治研究院中心实验室,山东济南250117

出　　处：《癌症》2001年第4期379-382,共4页Chinese Journal of Cancer

摘　　要：目的：探讨多药耐药相关蛋白 (multidrug resistance- associated protein， MRP)基因及 P-糖蛋白 (P- glycoprotein, P- gp)在恶性淋巴瘤 (malignant lymphomas， ML)中的表达与化疗疗效、临床耐药的关系。方法：应用半定量逆转录多聚酶链反应 (reverse transcriptase polymerase chain reaction， RT- PCR)和流式细胞术（ flow cytometry, FCM）检测了 46例 ML患者 MRP和 P- gp的表达水平。结果：复发患者 P- gp表达水平与阳性率均高于初治患者（ P< 0.001） ,而 MRP基因表达水平与阳性率在复发与初治患者间无显著性差异 (P >0.05)。 P- gp表达阳性患者的化疗有效率 (26.67％ )明显低于 P- gp表达阴性患者 (83.87％ )(P< 0.001)，而 MRP基因表达阳性患者与阴性患者的化疗有效率无差异 (P >0.05)。相关分析显示， MRP基因表达与 P- gp表达之间无明显相关性（ r=0.0818,P >0.05）。结论： P- gp表达与恶性淋巴瘤多药耐药相关，是其临床耐药的主要机制，而 MRP基因表达与化疗疗效未见相关。Objective： This study was designed to investigate the relationship between expression level of multidrug resistance- associated protein (MRP) or P- glycoprotein (P- gp) genes and chemotherapy efficacy or clinical drug resistance in the patients with malignant lymphomas. Methods： Using the methods of semi quantitative reverse transcription polymerase chain reaction (RT- PCR) and flow cytometry (FCM), The authors examined the expression level of MRP and P- gp of 46 lymphoma patients. Results： The expression level and positive rate of P- gp in the recurrent patients was higher than that in untreated patients (P< 0.001). There was no difference in MRP gene expression level and positive rate between recurrent and untreated patients (P >0.05). Chemotherapeutic effective rate in P- gp positive patients (26.67％ ) was lower than that in P- gp negative patients (83.87％ )(P< 0.001). While there was no difference between MRP gene positive and negative patients , their chemotherapy effective rate had no difference. Relevant analysis showed that there was no correlation between MRP and P- gp (r=0.0818, P >0.05). Conclusion： P- gp expression correlates to multidrug resistance, and is the major mechanism of clinical drug resistance of lymphomas, whereas, MRP gene does not appears to play any role in that course.

关 键 词：恶性淋巴瘤 聚合酶链反应 流式细胞术 P-糖蛋白 多药耐药相关蛋白 

分 类 号：R730.2[医药卫生—肿瘤]